by Scott Larrivee | Jun 26, 2025 | News
The following is a copy of a press release issued by Cellectar Biosciences Partnership Provides Long-Term Supply of Iodine-125 and Actinium-225 Supports Advancement of Radiotherapeutic Pipeline and Plans to Initiate Phase 1b Clinical Trial of CLR-125 for...
by Scott Larrivee | Jun 26, 2025 | Blog
Nusano’s CEO, Chris Lowe, recently spoke to Ravi Kumar for the Connor Group’s Breakthrough Work podcast. The discussion covered: How Chris went from being CFO to leading Nusano as their CEO How Nusano technology is changing pharma, energy, and other...
by Scott Larrivee | Jun 19, 2025 | News
Alpha-emitting radioisotope expected to play an essential role in next-generation targeted cancer therapies DURHAM, N.C. and WEST VALLEY CITY, Utah – June 19, 2025 – dGenThera, Inc., a biotechnology company pioneering theranostic molecular pairs, and Nusano, a...
by Scott Larrivee | Jun 17, 2025 | News
Agreement provides Ratio access to Nusano-produced radioisotopes for oncology diagnostics and therapeutics Accelerates Ratio’s clinical pipeline with copper-64 for PET imaging and lutetium-177 and actinium-225 for targeted therapy Bolsters both companies’...
by Scott Larrivee | Jun 11, 2025 | News, Utah
Reservations available now, commercial production deliveries begin Q1 2027 Proprietary process with reduced environmental impacts Efficient domestic supply chain needed to support projected growth in energy demand from increased electrification and energy-intensive...
